ALSO NOTED: Wyeth wins FDA blessing for hemophilia med; India considers compulsory licensing;

> Wyeth got the FDA's nod for its hemophilia drug Xyntha, which also got the green light to prevent surgical bleeding in patients with the disease; the company was named in a related patent infringement lawsuit filed by rival Novartis. Report

> India is considering issuing compulsory licenses for generic versions of two cancer drugs--Roche's Tarceva and Pfizer's Sutent--to be made in India and exported to Nepal, which cannot afford the drugs nor manufacture them. Report

> New research suggests that Crohn's disease patients should start with biologic drugs such as Johnson & Johnson's Remicade rather than reserving them for use after steroids and other remedies fail. Report

> PDL BioPharma has agreed to sell a Minnesota plant to Genmab for $240 million cash; the new owner plans to keep the facility's 170 workers. Report

> Endo Pharmaceuticals posted fourth-quarter profits of $50.6 million, more than triple its previous-period results; accounting charges weighed down the company's 4Q 2006 numbers. Report

> Ipsen got backing from Europe's Committee for Medicinal Products for Human Use for its gout drug Adenuric. Report

> Antisoma is sending out signals that it's looking for new acquisitions to add to its pipeline. Report

> Researchers at Novocell report a key breakthrough in their program to find a cure for diabetes. The company reports that the researchers were able to turn embryonic stem cells into insulin-producing cells in mice. Report

> The blog Eye on FDA sees lessons in the high number FDA approvable letters. Report

And Finally... Computers spot Alzheimer's more quickly and accurately than docs do. Report